Navigation Links
BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
Date:5/15/2009

tients, 58% for all Stage IV patients and 48% for Stage IV M1c patients. The 1-year survival of the patients who achieved PR, CR or surgical CR (n=15) was 93% compared to 48% for those with stable or progressive disease.

Commenting on these results, Dr. Neil N. Senzer of The Mary Crowley Cancer Research Center in Dallas, TX, the lead author for the presentation, said:

"Compared to any historical benchmarks for patients with Stage IIIc and Stage IV melanoma, this survival data, especially when coupled with a low toxicity profile, is provocative. Additionally, of the responses previously reported the vast majority have been maintained for up to more than three years from enrollment. I look forward to the results of the subsequent Phase III study which has recently initiated."

OPTiM Phase III Trial

The trial is a multi-national, open label, randomized Phase 3 study to assess the efficacy and safety of treatment with OncoVEX GM-CSF as compared to sub cutaneously administered GM-CSF in patients with unresectable stage III (b-c) and Stage IV (M1a-c) disease. The primary endpoint is the rate of durable (maintained for six months) objective response. Patients will have received at least one prior therapy for active disease which includes any type of therapy including investigational drugs. A total of 360 patients will be enrolled (240 to the OncoVEX GM-CSF arm and 120 to the control arm). The study design was agreed with the FDA under the Special Protocol Assessment ("SPA") process. The SPA process provides for a designation from the FDA that the trial's design, clinical endpoints and statistical analysis can be used for regulatory approval.

About Metastatic Melanoma

According to the American Cancer Society, more than 8,000 people died in the U.S. of me
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Canadians surveyed said they would participate in public health ... genetic conditions, only 80 per cent said they would ... their newborns, genomes.,Most newborns in North America have a ... of life in which a tiny amount of blood ... five to 54 conditions, depending on the state or ...
(Date:4/17/2014)... An anti-malarial treatment that lost its status as the ... a new lease of life, with new research indicating ... findings could revive the use of the cheap anti-malarial ... which claims the lives of more than half a ... parasite that causes malaria has developed resistance to chloroquine, ...
(Date:4/16/2014)... The Translational Genomics Research Institute (TGen) recently honored two ... their support of TGen,s research into brain, colon and ... Scottsdale. , Catherine Ivy, Founder and President of The ... McCain Leadership Award, named for U.S. Sen. John McCain ...
(Date:4/16/2014)... DOWNERS GROVE, Ill. April 16, 2014 According ... surveillance colonoscopy in average-risk patients with one to two ... 90 percent of cases. This may be an appropriate ... endoscopic database study to quantify adherence to guidelines for ...
(Date:4/15/2014)... fish caused nearly half of all injuries aboard commercial ... freezer-longliner vessels operating off the coast of Alaska, new ... those injuries and others aboard the two types of ... the research methods used in the study could help ...
Breaking Medicine News(10 mins):Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Changes in processing, handling could reduce commercial fishing injuries 2
... , PLYMOUTH MEETING, Pa., Nov. 16 In this ... are scrutinizing costs and being forced to make tough decisions affecting ... technologies clamoring for attention, knowing which ones to focus on can ... asked by health plans around the country, ECRI Institute(R) ( ...
... 16 With health care reform taking the national ... that some form of change is necessary. Many health care ... government-mandated change because innovation has already begun to occur organically ... defining that innovation and garnering attention in the industry. , ...
... Other Requests: Harmonize Regulations and Avoid Duplicate Fees ... products pose a significant food safety hazard, facilities producing these ... regulations proposed so far this year by Congress. These facilities ... which are know as the Pasteurized Milk Ordinance (PMO), that ...
... But risk is highest for women with aura, researchers find ... migraines have more than double the risk of ischemic stroke, ... study has found. , Ischemic stroke, the most common type ... cut off by plaque accumulation or a blood clot. , ...
... As many software companies work to create programs that ... are reported, a new study by researchers at Wake Forest ... not improve, but rather decreases the completeness and accuracy of ... Radiology , compared the accuracy and completeness of reporting test ...
... 2009Although women have made strides in the business world, ... leadership positions in the Fortune 500. Not surprisingly therefore ... and most industries are considered to be male-typed at ... positions within a handful of industries, these industries are ...
Cached Medicine News:Health News:ECRI Institute Issues Health Plan Watch List: 2010 Top 7 Technologies; Exclusive Insights in White Paper, Available for Free Download 2Health News:ECRI Institute Issues Health Plan Watch List: 2010 Top 7 Technologies; Exclusive Insights in White Paper, Available for Free Download 3Health News:Health Care Robots: Next Generation Decision-Making Software, Eliminates Manual Systems Labor 2Health News:Health Care Robots: Next Generation Decision-Making Software, Eliminates Manual Systems Labor 3Health News:Dairy Groups Urge Senators to Include Raw Milk Facilities in Food Safety Regulations 2Health News:Dairy Groups Urge Senators to Include Raw Milk Facilities in Food Safety Regulations 3Health News:Migraine Increases Likelihood of Stroke 2Health News:Structured reporting software creates less complete and accurate radiology reports than free text 2Health News:Structured reporting software creates less complete and accurate radiology reports than free text 3
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... reimbursement rates for home medical equipment and services (HME) ... as a result of Medicare,s bidding program going into ... largest metropolitan areas in the U.S. ... City, Miami, Orlando, Pittsburgh, and Riverside, California. The bidding ...
... Pa., Dec. 16, 2010 West Pharmaceutical Services, Inc. (NYSE: ... approved payment of the first-quarter 2011 cash dividend of $0.17 per ... shareholders of record on January 19, 2011. ... components and systems for injectable drug delivery, including stoppers and seals ...
Cached Medicine Technology:Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 2Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 3
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of total and direct bilirubin in serum or plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Medicine Products: